BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
2808627
Number of visits today
241
Number of downloads
2060627
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Pawinska-wasikowska K, Wieczorek A, Balwierz W, Bukowska-strakova K, Surman M, Skoczen S. Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia. Cancers 2022;14:458. [DOI: 10.3390/cancers14020458] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou G, Wang L, Tang X, Liu S, Li T, Liu Y, Chen F, Mai H, Liu S, Wen F, Wang Y. Blinatumomab therapy for B cell acute lymphoblastic leukemia accompanied by persistent or relapsed low-level MRD prior to hematopoietic stem cell transplantation in Chinese children: a case series. Bull Natl Res Cent 2023;47:30. [DOI: 10.1186/s42269-023-00999-x] [Reference Citation Analysis]
2 Blinatumomab. Reactions Weekly 2023;1944:159-159. [DOI: 10.1007/s40278-023-33678-y] [Reference Citation Analysis]
3 Chen B, Zou Z, Zhang Q, Chen K, Zhang X, Xiao D, Li X. Efficacy and safety of blinatumomab in children with relapsed/refractory B cell acute lymphoblastic leukemia: A systematic review and meta-analysis. Front Pharmacol 2022;13:1032664. [PMID: 36703737 DOI: 10.3389/fphar.2022.1032664] [Reference Citation Analysis]
4 Kyriakidis I, Mantadakis E, Stiakaki E, Groll AH, Tragiannidis A. Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas. Cancers (Basel) 2022;14:5022. [PMID: 36291806 DOI: 10.3390/cancers14205022] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345